Cargando…

Effect of Age on Clinical Trial Outcome in Participants with Probable Alzheimer’s Disease

BACKGROUND: Age may affect treatment outcome in trials of mild probable Alzheimer’s disease (AD). OBJECTIVE: We examined age as a moderator of outcome in an exploratory study of deep brain stimulation targeting the fornix (DBS-f) region in participants with AD. METHODS: Forty-two participants were i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Targum, Steven D., Fosdick, Lisa, Drake, Kristen E., Rosenberg, Paul B., Burke, Anna D., Wolk, David A., Foote, Kelly D., Asaad, Wael F., Sabbagh, Marwan, Smith, Gwenn S., Lozano, Andres M., Lyketsos, Constantine G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461716/ https://www.ncbi.nlm.nih.gov/pubmed/34151817 http://dx.doi.org/10.3233/JAD-210530

Ejemplares similares

A Phase II Study of Fornix Deep Brain Stimulation in Mild Alzheimer’s Disease
por: Lozano, Andres M., et al.
Publicado: (2016)

Brain structures and networks responsible for stimulation‐induced memory flashbacks during forniceal deep brain stimulation for Alzheimer's disease
por: Germann, Jürgen, et al.
Publicado: (2021)

Optimal deep brain stimulation sites and networks for stimulation of the fornix in Alzheimer’s disease
por: Ríos, Ana Sofía, et al.
Publicado: (2022)

Principles and management of neuropsychiatric symptoms in Alzheimer’s dementia
por: Nowrangi, Milap A, et al.
Publicado: (2015)

Alzheimer’s disease and the fornix
por: Oishi, Kenichi, et al.
Publicado: (2014)

Editorial: Alzheimer's Disease and the Fornix
por: Oishi, Kenichi, et al.
Publicado: (2016)

Time course of neuropsychiatric symptoms and cognitive diagnosis in National Alzheimer's Coordinating Centers volunteers
por: Wise, Elizabeth A., et al.
Publicado: (2019)

Associations between neuropsychiatric symptoms and incident Alzheimer’s dementia in men versus women
por: Liampas, Ioannis, et al.
Publicado: (2022)

Agitation in Alzheimer's disease: Novel outcome measures reflecting the International Psychogeriatric Association (IPA) agitation criteria
por: De Mauleon, Adelaide, et al.
Publicado: (2021)

Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress
por: Sabbagh, Marwan N., et al.
Publicado: (2019)

Psychosis in Alzheimer’s Disease
por: Ballard, Clive, et al.
Publicado: (2020)

New Acetylcholinesterase Inhibitors for Alzheimer's Disease
por: Mehta, Mona, et al.
Publicado: (2012)

Excitatory Neurons Derived from Human-Induced Pluripotent Stem Cells Show Transcriptomic Differences in Alzheimer’s Patients from Controls
por: Sagar, Ram, et al.
Publicado: (2023)

Editorial Introduction to the Special Issue from the International Symposium on Biomarkers for Alzheimer’s Disease and Related Disorders
por: Sabbagh, Marwan N.
Publicado: (2017)

Neuronal-Derived EV Biomarkers Track Cognitive Decline in Alzheimer’s Disease
por: Eren, Erden, et al.
Publicado: (2022)

Broader Considerations of Higher Doses of Donepezil in the Treatment of Mild, Moderate, and Severe Alzheimer's Disease
por: Berk, Camryn, et al.
Publicado: (2012)

Surface-Based Analysis on Shape and Fractional Anisotropy of White Matter Tracts in Alzheimer's Disease
por: Qiu, Anqi, et al.
Publicado: (2010)

Novel Therapeutics in Alzheimer's Disease
por: Sabbagh, Marwan, et al.
Publicado: (2012)

Editorial: A Time of Transition of Alzheimer's Disease in the Advent of Anti-Amyloid Monoclonal Antibodies
por: Tousi, Babak, et al.
Publicado: (2021)

Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology
por: Sabbagh, Marwan, et al.
Publicado: (2011)

Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer’s Dementia: Findings in Two Cohorts
por: Lue, Lih-Fen, et al.
Publicado: (2017)

Alzheimer’s disease beyond amyloid: strategies for future therapeutic interventions
por: Shi, Jiong, et al.
Publicado: (2020)

Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer’s dementia?
por: Crum, Jana, et al.
Publicado: (2018)

Potential Peripheral Biomarkers for the Diagnosis of Alzheimer's Disease
por: Patel, Seema, et al.
Publicado: (2011)

5HT6 Antagonists in the Treatment of Alzheimer’s Dementia: Current Progress
por: Andrews, Megan, et al.
Publicado: (2018)

Audio-digital recordings for surveillance in clinical trials of major depressive disorder
por: Targum, Steven D., et al.
Publicado: (2019)

Alzheimer's disease drug development pipeline: 2019
por: Cummings, Jeffrey, et al.
Publicado: (2019)

Alzheimer's disease drug development pipeline: 2020
por: Cummings, Jeffrey, et al.
Publicado: (2020)

Oral glucose tolerance testing to modulate plasma amyloid levels: A novel biomarker
por: Oh, Esther S., et al.
Publicado: (2015)

Is There Inflammatory Synergy in Type II Diabetes Mellitus and Alzheimer's Disease?
por: Lue, Lih-Fen, et al.
Publicado: (2012)

The Cause of Alzheimer’s Disease: The Theory of Multipathology Convergence to Chronic Neuronal Stress
por: Decourt, Boris, et al.
Publicado: (2022)

A cross-cultural comparison study of depression assessments conducted in Japan
por: Targum, Steven D, et al.
Publicado: (2013)

FDA position statement “Early Alzheimer's disease: Developing drugs for treatment, Guidance for Industry”
por: Sabbagh, Marwan N., et al.
Publicado: (2019)

Changes in QTc Interval in the Citalopram for Agitation in Alzheimer's Disease (CitAD) Randomized Trial
por: Drye, Lea T., et al.
Publicado: (2014)

Improving the Utility of Polygenic Risk Scores as a Biomarker for Alzheimer’s Disease
por: Vlachakis, Dimitrios, et al.
Publicado: (2021)

Fundamentals of applied probability theory
por: Drake, Alvin W.
Publicado: (1967)

Factors that influence survival in a probable Alzheimer disease cohort
por: Rountree, Susan D, et al.
Publicado: (2012)

Investigations of f-imperfections in an alternating gradient synchrotron with nonlinear forces
por: Fosdick, L D
Publicado: (1955)

KIF6 719Arg Carrier Status Association with Homocysteine and C-Reactive Protein in Amnestic Mild Cognitive Impairment and Alzheimer's Disease Patients
por: Malek-Ahmadi, Michael, et al.
Publicado: (2013)

Differences in Cerebrospinal Fluid Biomarkers between Clinically Diagnosed Idiopathic Normal Pressure Hydrocephalus and Alzheimer’s Disease
por: Tsai, Andrew, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_e25uejulq51lfgjl0l5p0f4qcd